PT-141, the first in a new class of therapies called melanocortin agonists, works through a mechanism of action involving the central nervous system rather than directly on the vascular system. As a result, it may offer significant safety and efficacy benefits over currently available products, including Viagra®,

Levitra® and Cialis®, which belong to the class of phosphodiesterase-5 (PDE-5) inhibitors.

PT-141 is nasally administered and is both non-invasive and fast acting. Importantly, PT-141 is not expected to be contraindicated in patients taking nitrates for the treatment of cardiovascular disease. Clinical studies have demonstrated PT-141 to be safe and effective and to improve patient experience

PT-141 has been evaluated in four Phase 2 efficacy studies enrolling more than 300 men. Study data have been presented at several scientific conferences and PT-141 has been the topic of numerous journal articles.